Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: jjs64 who wrote (80698)	10/2/2002 2:23:13 PM
From: StockDung	Read Replies (1) \| Respond to of 122087

"Geoff Eiten sets a high standard for creativity in finding undiscovered micro-cap stocks. His OTC Growth Stock Watch is a "must-read" for my staff at Westergaard Publishing Corporation and, indeed, for any analyst or portfolio manager working with stocks under $100 million market cap." - John Westergaard, president, Westergaard Publishing Corp. "OTC Growth Stock Watch has an impressive record of finding emerging growth companies before they become well known. Geoff Eiten’s analysis of each company is one of the most thorough and comprehensive that I have read." - Richard Geist, editor, Strategic Investing 216.239.51.100

To: jjs64 who wrote (80698)	10/2/2002 2:36:08 PM
From: StockDung	Respond to of 122087

Can't Quantify the Va l u e Our research fell short in finding companies or portfolio managers buoyant about the value of fee-based research. Understandably, companies ponying up the funds aren't anxious to talk about their experiences. Robert Benou, president of Conolog, followed the advice of Geoff Eiten to put out a lot of news. Benou believes it helped in keep- ing the price from taking a "nosedive" when the market fell in the spring of 2000, and to pick up when some recovery occurred. Richard Twardowski, IR director at IVG Corp., can't say that the heavy communications urged by Moebius editor Steve Reid has impacted stock price, but he says that it did serve to boost trading volume. And Richard Pierce, CEO at Laredo, said its source, Revealer, "generat- ed a fair number of calls, but it's hard to say what influ- ence it has had on stock price." On the investment side, Ken Sevinsky, J r. , senior portfolio manager at Fifth Third Bancorp in Cincinnati, sees a place for paid research among small cap companies. But he also has his doubts. "I wonder how you draw the line of being objective while the company you are covering is paying you," comments Sevinsky. Objectivity? Chuck Hill, director of research for Thomson Financial/First Call, issues a warning to investors about fee research. "If there is no analyst's name on the research, then buyer bewa r e," says Hill. About the opportunity for companies to make the investment screens of institutions requiring at least one analyst earnings f o r e c a s t , Hill has bad news. " We clearly would not use somebody that does research and was paid for it," he says. A final word comes from Robert J. F l a h e r t y, l o n g t i m e e d i t o r of Equities magazine, which specializes in under- standing small companies. Improved liquidity may be the chief benefit of paid-for research, suggests Flaherty. Plus, it's better than no research,he adds, as long as it's honest. What he doesn't like is stuff like "`This is the next General Motors.' They're trying to have the company take on the attributes of the giants." Flaherty says that companies and investors should want information in these reports about management and about risk. " T h e r e 's a lack of management background in these pieces." Risk needs to be disclosed,especially about competition, adequacy of financing, and other basic financial considerations, he adds. "And, any projections should be reasonable." Joseph P. Hassett is research editor of Shareholder Value. He has an extensive career as a corporate investor relations officer and consultant. Bill Mahoney is executive editor of Shareholder Value. SV Shareholder Value M a y / June 2001 33 essentially is individual investors . 216.239.37.100

To: jjs64 who wrote (80698)	10/2/2002 2:42:05 PM
From: afrayem onigwecher	Respond to of 122087

Up 0.77 (+10.03%) GMXX - GENEMAX CORP Last Price: 8.45 at 14:01 EDT Change: Up 0.77 (+10.03%)

To: jjs64 who wrote (80698)	10/2/2002 6:27:51 PM
From: afrayem onigwecher	Read Replies (3) \| Respond to of 122087

TTR in talks to sell most assets to Macrovision 10/2/2002 6:14:29 PM NEW YORK, Oct 2 (Reuters) - Struggling anti-piracy product maker TTR Technologies Inc. (TTRE) on Wednesday said it is in talks to sell most of its assets to Macrovision Corp. (MVSN) , its primary technology partner and one of its biggest investors. Alerts Company: Ttr Technologies Inc Create Company: Macrovision Corporation Create TTR, the maker of the SafeAudio copy protection product, said the sale would include all of its intellectual property rights in the music protection and digital rights management business. The New York company, whose shares closed at 16 cents on Wednesday, said it had agreed to negotiate exclusively with Macrovision until Nov. 2. TTR aims to pare its costs by one-fourth over the coming 12 months, and said it is winding down all research, design and development activities at its Israel subsidiary TTR Technologies Ltd. The company said it would move any remaining related activities to the United States. TTR in September said company Chief Executive Daniel Stein had assumed the additional role of president, replacing resigning co-founder Marc Tokayer. Gershon Tokayer, Marc Tokayer's brother and the company's vice president of business development, also resigned. © Reuters 2002. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

To: jjs64 who wrote (80698)	10/9/2002 5:55:17 PM
From: StockDung	Respond to of 122087

PHANDOC BLOOPERS, BLEEPERS AND SCAMDOC RIPPOFFS: HARTCOURT, A NASDAQ LISTED COMPANY Dr. Alan V. Phan, Chairman of the Board and Director. Dr. Phan has over 30years of experience in business management. He obtained his academic trainingand degrees at Pennsylvania State University and Sussex College of Technology.As Executive Vice President of Em Kay Group and Eisenberg Company, heestablished 11 industrial projects including real estate developments in Asiaand South America. Dr. Phan has been a founder and Chairman of the Board and Chief Executive Officer of The Hartcourt Companies, Inc., a NASDAQ listed company, since August 1990. ostman.com

To: jjs64 who wrote (80698)	10/21/2002 7:31:08 PM
From: afrayem onigwecher	Respond to of 122087

GeneMax Corp. Announces Appointment of Dr. Soldano Ferrone To Its Scientific Advisory Board BLAINE, Wash., Oct. 14 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX, Frankfurt: GX1) announces today that Dr. Soldano Ferrone, M.D., Ph.D. has joined the Company's Scientific Advisory Board. Dr. Ferrone is Chairman of the Department of Immunology at the Roswell Park Cancer Institute and a Professor of Microbiology at the School of Medicine and Biomedical Sciences at SUNY, both in Buffalo, New York. Dr. Ferrone is a world expert in the area of cellular immunology, and has published over 725 papers. These include work on TAP (transporters associated with antigen processing), the area of GeneMax's lead product development, and in HLA class I antigen downregulation in human cancers. Dr. Ferrone completed his M.D. and Ph.D. degrees at the University of Milano, Italy. His academic career has included positions at the University of Milan and at the Scripps Clinic and Research Foundation in La Jolla, CA, and professorships at Columbia University and New York Medical College. His numerous awards include the Alexander von Humboldt award in 1988 and 1997. He has been actively involved with Committees of the National Cancer Institute, Biological Resources Branch and National Institutes of Health Experimental Immunology Study Section. Professor Ferrone said, "I am pleased to be joining GeneMax's Scientific Advisory Board. I believe that the TAP technology that is being developed by the company is supported by the information in the literature and has a sound rationale as a potential new cancer treatment." Roswell Park Cancer Institute (RPCI) is a world leader in the treatment of cancer. It is one of only 41 centers in the United States holding the National Cancer Institute designation of "comprehensive cancer center." This designation is awarded to institutes that combined research, treatment and educational programs that have met rigorous national standards, and made fundamental contributions to reducing the cancer burden. Ronald L. Handford, President & CEO of GeneMax said, "Dr. Ferrone's extensive experience in the research and development of immunotherapies for cancer will be a great asset to GeneMax and its Scientific Advisory Board. We are looking forward to working closely with him towards the goal of rapidly bringing our lead product to the clinic and expanding our product pipeline." Dr. Ferrone joins a broadly-scoped team on the GeneMax Scientific Advisory Board including Dr. Wilfred A. Jefferies, GeneMax's Chief Scientific Officer and Professor of Biotechnology at the University of British Columbia, Dr. James Hogg, Professor of Pathology at the University of British Columbia, Dr. Victor Ling, Vice President Research at the B.C. Cancer Agency and Dr. Bernard Moss of Bethesda, Maryland, a member of the National Academy of Science and an expert in the field of expression vector systems. About GeneMax: GeneMax is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection. GENEMAX CORP common stock is traded on the OTC Bulletin Board in the United States under the symbol GMXX and on the Frankfurt Stock Exchange under the symbol GX1. Stock Exchange Information: (Symbol: OTCBB - GMXX, Symbol FWB - GX1, WKN: 645096, ISN: US36870Q1031). SAFE HARBOR STATEMENT THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Make Your Opinion Count - Click Here tbutton.prnewswire.com SOURCE GeneMax Corp. CO: GeneMax Corp. ST: California SU: PER prnewswire.com 10/14/2002 11:18 EDT